Evaluating new drugs that target a key pathway in Parkinson's disease
In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease
This study is looking at new tiny drugs that could help slow down Parkinson's disease by helping the body get rid of damaged parts of cells, and it's testing these drugs in animals to see if they can protect against nerve damage.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vincere Biosciences, INC. NIH-funded |
| Lab location | 1 site (Cambridge, UNITED STATES) |
| Project ID | NIH-10931716 on NIH RePORTER |
What this research studies
This research focuses on developing small molecules that inhibit USP30, a protein involved in the mitophagy pathway, which is crucial for maintaining healthy mitochondria. By targeting this pathway, the research aims to enhance the removal of damaged mitochondria, potentially slowing the progression of Parkinson's disease. The approach includes testing these small molecules in animal models to assess their effectiveness in protecting against neurodegeneration linked to Parkinson's. If successful, this could lead to new therapeutic options for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are seeking new treatment options.
Not a fit: Patients with Parkinson's disease who are not responsive to experimental therapies or those in advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment that slows or halts the progression of Parkinson's disease.
How similar studies have performed: While there has been success in targeting the mitophagy pathway in smaller models, this approach in larger animal models is relatively novel and untested.
Where this research is happening
Cambridge, UNITED STATES
- Vincere Biosciences, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Behrouz, Bahareh — Vincere Biosciences, INC.
- Study coordinator: Behrouz, Bahareh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.